Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer - Wikidata - wikimedia - TriplyDB

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

http://www.wikidata.org/entity/Q34628085

about

The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients Genomic diversity of colorectal cancer: Changing landscape and emerging targets Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative Setting Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies Impact of somatic mutations on patterns of metastasis in colorectal cancer Molecular profiling in the treatment of colorectal cancer: focus on regorafenib BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Beyond RAS and BRAF: a target rich disease that is ripe for picking Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics Surgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation Status Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution.Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.A systems biology approach to the global analysis of transcription factors in colorectal cancer.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.Biology of colorectal cancer.Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer Primary tumor location as a prognostic factor in metastatic colorectal cancer.

P2860

Q26738665-95CA4EB1-7230-4EB5-A119-CF441ABFF36B Q26739052-02B95FED-35F8-469F-AD62-E4223D15268E Q26741009-EC261A9F-95F7-4AF6-B51C-B74CB87C5B86 Q26747329-9F304F3D-3E62-4DAE-9146-F878B6000D2D Q26749002-AF6E2480-C0A1-4E05-96E2-A010FC3B5DFF Q26751035-FA8F90E1-CCD6-4471-98E6-9B6048DF5C32 Q26772267-788F7D11-B503-464D-94A2-E5256335F335 Q26772276-C708B86C-31D1-46DB-9A8E-ECB035467893 Q26772279-C24F5863-96ED-4A10-887C-F9B6AB864DE8 Q26778296-0F415B67-E170-4725-9B03-3ABD7E19B01E Q27852942-6F595C3E-686C-4469-A151-23C683CB8FA7 Q27853121-A197D69E-D82B-4745-8D2F-36D3A36EF774 Q27853216-22ECBD06-C157-4AFD-8F5B-BFF0F8D32074 Q27853224-DA2D8A9A-93B5-4ED8-8536-4174116F349B Q28066095-D7E5ADF2-6999-4F5A-9496-26D94CD795E2 Q28066158-DE16CA20-7466-4D8A-8C8C-5548170CD021 Q28075777-BD26C44C-F9BA-43F8-B4C5-A74DD0AA649E Q28077199-B29F4279-2570-4A05-BD55-50250C333853 Q28080176-5AC18E0C-FE08-4AF5-9E5E-CD0B39A75FC5 Q30358990-31B73235-4ECB-48D8-BBDC-C83A9E8E4B26 Q30967175-FE7BB15E-BADF-413C-A4A2-D79230A5665F Q33813216-0ABEE714-6AE1-4C18-88DA-C0615B1A9972 Q34067781-73B4BA7B-C8EA-4E8B-90C0-0172F14DA53E Q34308855-0689846E-A36A-4A57-8823-4009E5ECF653 Q34361370-C6EBAE93-1521-4AD7-87A9-1FDAA94CDB5F Q34362289-49BF98E2-D235-4C9A-A49E-167FBBE055B2 Q34442771-294D8110-E84C-4664-A212-3FEFF677DBE3 Q34669618-46D02B3C-AF02-46B6-BE84-1418B04FB358 Q34703562-A445594B-7F7F-40E2-BA79-197D5B164E1B Q35012020-1AC7A9ED-999D-477A-B6B4-0E358609E2B5 Q35098287-E90AFD5B-03A4-4A34-9F6F-64DBB90161FA Q35124790-FDF44FED-C2AE-4DD5-AAC0-8AD500DF6EEE Q35187723-35BC98D2-08FD-4D0A-A6CB-4A5AD0839668 Q35677169-925018B3-C1F0-48C9-964A-7BAEA56A360C Q35685684-076866FB-30F3-4747-A8AE-54DA3EDED043 Q35773077-DC070E03-6428-4E00-B1AC-FAAFB0B2FFB4 Q35777233-BC59BE6E-7D10-4211-9AEA-CDD54C95BD44 Q35870363-98667E9A-7FD6-406D-90E2-F4BC1D155946 Q35911017-0E542FF3-A136-4AC9-9D19-1DF83A456BC0 Q36047405-042A02CF-6F07-4671-911E-B46D5C0499F4

P2860

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

http://www.wikidata.org/entity/Q34628085

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@ast

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@en

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@nl

type

label

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@ast

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@en

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@nl

prefLabel

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@ast

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@en

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@nl

P1433

Q34628085-C2ACB6F4-FBC0-41AA-9C46-B840AC80425D

P1476

Q34628085-05C31DA8-B4F9-4E1B-9F6E-6E957365F9A6

P2093

Q34628085-2AD8A2CA-95FA-4157-9A9B-2A6BE9213900

Q34628085-7C629C46-E9FA-4E5A-B335-05DD4EBB710A

Q34628085-90E3EA4D-3163-4DE2-99A1-0DB07EC23954

Q34628085-A879CFB6-AE6B-48A1-B352-5F1009F4723C

Q34628085-A92B55A7-1CFB-47A7-B8BC-008CA563F426

Q34628085-FF23BAA1-577E-42FA-92EA-C634857B5B3C

P2860

Q34628085-09DF4F15-2483-4D8F-A1C9-620FF3BA3260

Q34628085-298C5F34-046A-4C75-9E61-8F620B885EB0

Q34628085-316E37B5-2905-4AB6-83AC-124C67D9A634

Q34628085-45828B25-7B67-4E51-9D94-53AF9F2DC934

Q34628085-47514D1C-5B60-482B-BD58-F20A586A2063

Q34628085-54527322-6163-4E9A-A0F7-78A7607ED710

Q34628085-59D0B684-7D0F-4A15-859F-DB337F15059A

Q34628085-69EA8FA0-9E0E-4FD7-86F2-E092935B743C

Q34628085-6C4E513B-910D-4F14-B713-6ABC02FD4B0C

Q34628085-7002E67A-1010-432A-9865-51743FE07DAF

P304

Q34628085-5C5C71CF-0ED4-4975-9D55-41DE78B23871

P31

Q34628085-498C072F-9FA6-43F4-9943-AED2533FEA64

P356

Q34628085-4AE27607-2903-43DC-A01C-816F23210BC5

P407

Q34628085-2CF09A0F-391C-4BAC-B89A-B363CBF7D38F

P433

Q34628085-77857CDA-9F52-4983-9792-987DDAC65F1A

P478

Q34628085-BD57BEEF-E4A9-47BD-8902-986AA8C51727

P50

Q34628085-18EDD35F-8E34-45E1-ACA3-B44B553B3FD6

Q34628085-73C2B3DC-DC20-41D0-B0D0-999B274BB8B6

Q34628085-9C5FF17D-4C89-46D5-AA7E-52E336839625

Q34628085-EBDB7139-805E-4752-A31A-7E3C4E7D8339

P577

Q34628085-30A7ABEA-0B40-4C0E-8030-86B96C852322

P5875

Q34628085-467FBCE4-C92C-45F9-8EBD-E24F254CF77D

P698

Q34628085-853A44B5-A4C4-4FCA-8AED-B24DE75B7961

P921

Q34628085-0F924005-216D-4ADC-AFD1-F2DA7D0B701F

Q34628085-4DFA2277-5A59-4B70-9D28-3BF68CD0DA5A

P932

Q34628085-0BD088EE-4718-4FF5-8853-06413B14E431

P356

P1433

P1476

Impact of BRAF mutation and mi ...... n metastatic colorectal cancer

@en

P2093

Atin Agarwal

http://www.w3.org/2001/XMLSchema#string

Ben Tran

http://www.w3.org/2001/XMLSchema#string

Christopher H Lieu

http://www.w3.org/2001/XMLSchema#string

Dipen M Maru

http://www.w3.org/2001/XMLSchema#string

Jeanne Tie

http://www.w3.org/2001/XMLSchema#string

Zhi-Qin Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Systematic review of microsatellite instability and colorectal cancer prognosis

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

P304

4623-4632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.26086

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50941175

http://www.w3.org/2001/XMLSchema#string

P698

21456008

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4257471

http://www.w3.org/2001/XMLSchema#string